Microhemodynamic consequences of tumor angiogenesis targeting using the tyrosine kinase inhibitor SU11248

被引：0
|
作者：
Czabanka, M.
Erber, R.
Vinci, M.
Ullrich, A.
Vajkoczy, P.
机构：
[1] Univ Heidelberg, Klinikum Mannheim, Dept Neurosurg, Mannheim, Germany
[2] Max Planck Inst Biochem, D-82152 Martinsried, Germany
来源：
JOURNAL OF VASCULAR RESEARCH | 2006年 / 43卷 / 06期
关键词：
D O I：
暂无
中图分类号：
Q4 [生理学];
学科分类号：
071003 ;
摘要：
引用
收藏
页码：564 / 564
页数：1
相关论文
共 50 条
  • [1] Discovery of SU11248, a novel tyrosine kinase inhibitor targeting VEGF and PDGF receptors.
    Sun, L
    Liang, C
    Shirazian, S
    Zhou, Y
    Cui, J
    Fukuda, JY
    Chu, JY
    Nematalla, A
    Wang, XY
    Chen, H
    Sistla, A
    Luu, TC
    Tang, F
    Wei, J
    Tang, C
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 225 : U174 - U174
  • [2] Preclinical evaluation of the tyrosine kinase inhibitor SU11248 for the treatment of breast cancer
    Abrams, TJ
    Murray, LJ
    Pryer, NK
    Garcia, R
    Potapova, O
    Laird, AD
    Manning, JWC
    Pesenti, E
    Cherrington, JM
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S75 - S75
  • [3] SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells
    Gu, Jian-Wei
    Tucker, Kevan B.
    Huang, Min
    Young, Emily
    Wells, Jeremy
    Pan, Zhi-Jun
    FASEB JOURNAL, 2010, 24
  • [4] SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells
    Young, Emily
    Miele, Lucio
    Tucker, Kevan B.
    Huang, Min
    Wells, Jeremy
    Gu, Jian-Wei
    CANCER BIOLOGY & THERAPY, 2010, 10 (07) : 703 - 711
  • [5] Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248
    Potapova, Olga
    Laird, A. Douglas
    Nannini, Michelle A.
    Barone, Angela
    Li, Guangmin
    Moss, Katherine G.
    Cherrington, Julie M.
    Mendel, Dirk B.
    MOLECULAR CANCER THERAPEUTICS, 2006, 5 (05) : 1280 - 1289
  • [6] SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
    O'Farrell, AM
    Abrams, TJ
    Yuen, HA
    Ngai, TJ
    Louie, SG
    Yee, KWH
    Wong, LM
    Hong, W
    Lee, LB
    Town, A
    Smolich, BD
    Manning, WC
    Murray, LJ
    Heinrich, MC
    Cherrington, JM
    BLOOD, 2003, 101 (09) : 3597 - 3605
  • [7] SU11248: An oral multitargeted tyrosine kinase inhibitor with promising activity in metastatic renal cell carcinoma
    Sternberg, CN
    ANNALS OF ONCOLOGY, 2005, 16 : 17 - 17
  • [8] The anti-tumor effects of SU11248, a class III receptor tyrosine kinase inhibitor, against a variety of human hematological malignancies
    Ikezoe, T
    Bandobashi, K
    Yang, Y
    Saito, T
    Togitani, K
    Tasaka, T
    Koeffler, HP
    Taguchi, H
    BLOOD, 2005, 106 (11) : 784A - 784A
  • [9] Nonclinical safety evaluation of sunitinib (SU11248; SUTENT), a novel multitargeted tyrosine kinase inhibitor for treatment of cancer
    Patyna, S.
    Heward, J. K.
    Evering, W.
    TOXICOLOGIC PATHOLOGY, 2007, 35 (01) : 188 - 188
  • [10] Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate
    Prenen, H
    Cools, J
    Mentens, N
    Folens, C
    Sciot, R
    Schöffski, P
    Van Oosterom, A
    Marynen, P
    Debiec-Rychter, M
    CLINICAL CANCER RESEARCH, 2006, 12 (08) : 2622 - 2627
12345